The global anti-neoplastic pharmaceutical agents market is valued at US$ 10,126.71 million as of 2022. The market is expected to grow at a CAGR of 11% during 2022-2032, and by 2032, it is expected to reach a valuation of US$ 28,754 million.
An increase in the number of cancer cases across the world is expected to surge the sales of anti-neoplastic pharmaceutical agents during the forecast period. This is because anti-neoplastic drugs are being used in immunotherapy, radiotherapy, etc., for treating metastatic tumors.
Moreover, a rising clamor for an affordable method to cure cancer might as well surge the demand for anti-neoplastic pharmaceutical agents. One of the most important factors driving the market growth is the rising government initiatives to treat cancer and neoplasm cases.
Furthermore, massive technological developments are expected to shape the entire healthcare sector. This is projected to massively impact the anti-neoplastic pharmaceutical agents market during the forecast period.
Lack of awareness regarding the application of anti-neoplastic pharmaceutical agents is expected to challenge the market growth during the forecast period. Apart from that, many people in developing and underdeveloped nations do not know much about the symptoms associated with neoplasms. Moreover, higher cost associated with anti-neoplastic agents is also expected to hinder market growth.
Furthermore, the unavailability of a favorable regulatory framework is expected to pose some challenges. Apart from that, the application of anti-neoplastic pharmaceutical agents also has some adverse effects on the human body, which might affect the market growth.
Based on the anti-neoplastic agents’ classification on the type of cancer, the breast cancer segment currently has the highest market share. As per the data released by WHO in 2020, of all the cancer cases, there was a maximum number of patients who were suffering from breast cancer (2.26 million). Since then, the numbers have been rising, reflecting a huge anti-neoplastic pharmaceutical agents market.
| Attributes | Value |
|---|---|
| Anti-neoplastic Pharmaceutical Agents Market Value (2022) | US$ 10,126.71 Million |
| Anti-neoplastic Pharmaceutical Agents Market Forecast Value (2032) | US$ 28,754 Million |
| Anti-neoplastic Pharmaceutical Agents Market Expected CAGR (2022 to 2032) | 11% |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
Based on the regional analysis, the North American region has the largest market share and is expected to retain the top position during the forecast period. An increased number of contagious diseases, coupled with a highly evolved healthcare sector in North America, is driving the anti-neoplastic pharmaceutical agents market growth. Apart from that, massive government investment in the healthcare sector is expected to strengthen the market.
If we talk about the fastest-growing market, it is Asia-Pacific. Massive investment by the governments in the region for the development of healthcare infrastructure is expected to drive market growth. Moreover, increased consumer awareness regarding the availability of these medical facilities is expected to surge the market's growth during the forecast period.
In a recent study published by the Journal of Controlled Release, it was showcased how a novel method for delivering anti-cancer drugs conjugated to modified cell-penetrating peptides can be implemented to treat Blood-Brain Barrier.
Principal Consultant
Some of the key players in manufacturing of anti-neoplastic pharmaceutical agents market include GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Eli Lilly and Company, Bristol-Myers Squibb Company, Becton, Dickinson and Company, Pfizer Inc., Novartis AG, AstraZeneca, Gilead, Accord Healthcare, and many others.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
The global anti-neoplastic pharmaceutical agents market is segmented based on type of cancer, anti-neoplastic pharmaceutical agents, and regional presence.
1. Executive Summary 2. Industry Introduction, including Taxonomy and Market Definition 3. Market Trends and Success Factors, including Macro-economic Factors, Market Dynamics, and Recent Industry Developments 4. Global Market Demand Analysis and Forecast, including Historical Analysis and Future Projections 5. Pricing Analysis 6. Global Market Analysis and Forecast 6.1. Type Of Cancer 6.2. Type Of Anti-Neoplastic Pharmaceutical Agents 7. Global Market Analysis and Forecast, By Type Of Cancer 7.1. Single-stage 7.2. Double-stage 7.3. Breast Cancer 7.4. Bladder Cancer 7.5. Cervical Cancer 7.6. Gynecological Cancer 7.7. Lung Cancer 7.8. Leukemia 7.9. Other Cancer Types (Anal Cancer, Bone Marrow Cancer, Colon Cancer, Eye Cancer, Osteo Sarcoma, Wilms Tumour, Larynx Cancer, Testicular Cancer, and Rectal Cancer) 8. Global Market Analysis and Forecast, By Type Of Anti-Neoplastic Pharmaceutical Agents 8.1. Alkylating Agents 8.2. Antimetabolites 8.3. Antitumor Antibiotics 8.4. Natural Products 8.5. Plant Products 8.6. Microorganism Products 8.7. Hormones and Antagonists 9. Global Market Analysis and Forecast, By Region 9.1. North America 9.2. Latin America 9.3. Western Europe 9.4. Eastern Europe 9.5. Asia Pacific 9.6. East Asia 9.7. MEA 10. North America Sales Analysis and Forecast, by Key Segments and Countries 11. Latin America Sales Analysis and Forecast, by Key Segments and Countries 12. Western Europe Sales Analysis and Forecast, by Key Segments and Countries 13. Eastern Europe Sales Analysis and Forecast, by Key Segments and Countries 14. Asia Pacific Sales Analysis and Forecast, by Key Segments and Countries 15. East Asia Sales Analysis and Forecast, by Key Segments and Countries 16. MEA Sales Analysis and Forecast, by Key Segments and Countries 17. Sales Forecast by Type Of Cancer and Type Of Anti-Neoplastic Pharmaceutical Agents for 30 Countries 18. Competition Outlook, including Market Structure Analysis, Company Share Analysis by Key Players, and Competition Dashboard 19. Company Profile 19.1. F. Hoffmann-La Roche Ltd 19.2. Eli Lilly and Company 19.3. Bristol-Myers Squibb Company 19.4. Becton, Dickinson and Company 19.5. Pfizer Inc. 19.6. Novartis AG 19.7. AstraZeneca 19.8. Gilead 19.9. Accord Healthcare
Explore Healthcare Insights
View Reports
Anti-Neoplastic Pharmaceutical Agents Market
